Clinical Trial Update: Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether reduced dosing of granulocyte colony-stimulating factor is effective at preventing febrile neutropenia in breast cancer patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Granulocyte Colony Stimulating Factor (granulocyte colony-stimulating factor (G-CSF))

Snippet

Sponsor: Jules Bordet Institute | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN